Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
VANCOUVER, British Columbia, March 02, 2017 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, will report its financial results for the year ending December 31, 2016 and will provide a general business update on Thursday, March 9, 2017 after U.S. financial markets close. Aquinox will host a conference call and live audio webcast on Thursday, March 9th, 2017 at 4:30 PM (ET) / 1:30 PM (PT).
Conference Call and Webcast Details:
Date: Thursday, March 9th, 2017
Time: 4:30 PM (ET) / 1:30 PM (PT)
Toll-free: (866) 357-7878
International: (315) 625-3088
Conference ID: 72144360
Webcast URL: http://edge.media-server.com/m/p/askid88w
The live webcast may be accessed through the "Events & Presentations" page in the "Investor Relations" section of the company's website at www.aqxpharma.com.
The archived webcast will also be available on Aquinox's website approximately two hours after the event and will be available for replay for at least 30 days after the event.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. In September 2016, we began enrolling patients in a Phase 3 clinical trial of AQX-1125 in our lead indication, Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Other indications are under consideration for future investigation. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
